快速大剂量环磷酰胺作为桥梁治疗多发性骨髓瘤的先进疗法。

EJHaem Pub Date : 2024-10-20 DOI:10.1002/jha2.1039

Marcus Marable, Kaitlin Kelly, Jennifer H. Cooperrider, Andrzej Jakubowiak, Benjamin A. Derman

{"title":"快速大剂量环磷酰胺作为桥梁治疗多发性骨髓瘤的先进疗法。","authors":"Marcus Marable, Kaitlin Kelly, Jennifer H. Cooperrider, Andrzej Jakubowiak, Benjamin A. Derman","doi":"10.1002/jha2.1039","DOIUrl":null,"url":null,"abstract":"<p>Patients with relapsed/refractory multiple myeloma proceeding with chimeric antigen receptor (CAR) T-cell therapy or bispecific antibodies (BsAb) may need bridging therapy to realize their benefits. We evaluated the efficacy and safety of rapid, peripheral, high-dose cyclophosphamide (TurboCy) in 15 patients intending to proceed with CAR T-cell therapy, BsAbs, or long-term regimens. The overall response rate was 80% and the clinical benefit rate was 100% in a heavily pretreated high-risk cohort. Cytopenias were common but no deaths occurred during bridging. All patients proceeded to their next line of intended therapy. TurboCy is an effective and safe bridging strategy.</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"5 6","pages":"1260-1264"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647735/pdf/","citationCount":"0","resultStr":"{\"title\":\"Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma\",\"authors\":\"Marcus Marable, Kaitlin Kelly, Jennifer H. Cooperrider, Andrzej Jakubowiak, Benjamin A. Derman\",\"doi\":\"10.1002/jha2.1039\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Patients with relapsed/refractory multiple myeloma proceeding with chimeric antigen receptor (CAR) T-cell therapy or bispecific antibodies (BsAb) may need bridging therapy to realize their benefits. We evaluated the efficacy and safety of rapid, peripheral, high-dose cyclophosphamide (TurboCy) in 15 patients intending to proceed with CAR T-cell therapy, BsAbs, or long-term regimens. The overall response rate was 80% and the clinical benefit rate was 100% in a heavily pretreated high-risk cohort. Cytopenias were common but no deaths occurred during bridging. All patients proceeded to their next line of intended therapy. TurboCy is an effective and safe bridging strategy.</p>\",\"PeriodicalId\":72883,\"journal\":{\"name\":\"EJHaem\",\"volume\":\"5 6\",\"pages\":\"1260-1264\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647735/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJHaem\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jha2.1039\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.1039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

复发/难治性多发性骨髓瘤患者进行嵌合抗原受体（CAR） t细胞治疗或双特异性抗体（BsAb）治疗可能需要桥接治疗才能实现其益处。我们评估了快速、外周、大剂量环磷酰胺（TurboCy）在15名打算继续进行CAR -t细胞治疗、bsab或长期方案的患者中的有效性和安全性。在大量预处理的高危队列中，总有效率为80%，临床获益率为100%。桥接期间细胞减少常见，但无死亡发生。所有的患者都进行了下一轮的治疗。TurboCy是一种有效且安全的桥接策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma

Patients with relapsed/refractory multiple myeloma proceeding with chimeric antigen receptor (CAR) T-cell therapy or bispecific antibodies (BsAb) may need bridging therapy to realize their benefits. We evaluated the efficacy and safety of rapid, peripheral, high-dose cyclophosphamide (TurboCy) in 15 patients intending to proceed with CAR T-cell therapy, BsAbs, or long-term regimens. The overall response rate was 80% and the clinical benefit rate was 100% in a heavily pretreated high-risk cohort. Cytopenias were common but no deaths occurred during bridging. All patients proceeded to their next line of intended therapy. TurboCy is an effective and safe bridging strategy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

EJHaem

自引率

0.00%

发文量